Honokiol specifically inhibits PI3K/mTOR signaling activation in gliomas [173, 175], promotes the elimination of GSCs, and reverses TMZ resistance using GBM8401 SP cells, which appear to have higher expression of MGMT and to be more resistant to TMZ. The gene discussed is MTOR; the disease is central nervous system cancer.